RC108 + furmonertinib

RC108 + furmonertinib is an investigational combination therapy for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations and MET overexpression. RC108 is an antibody-drug conjugate (ADC) targeting c-Met (hepatocyte growth factor receptor), acting as both a tubulin inhibitor and c-Met inhibitor. Furmonertinib is a third-generation, oral, highly brain-penetrant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively targets mutant forms of EGFR including T790M and exon 20 insertions. The combination aims to address resistance mechanisms in NSCLC patients who have failed prior EGFR-TKI therapies by simultaneously inhibiting both MET-driven and EGFR-driven tumor pathways.